QQQ ()
DIA ()
SPY ()
TLT ()
GLD ()
$ na
-- x --
-- x --
-- - --
-- - --
--
na
--
--
--
TBD
--
-- (--)
--
TBD --
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 uk-health-agency-recommends-gsk-backed-viiv-healthcares-apretude-as-injectable-hiv-treatment

NICE recommends ViiV Healthcare's Apretude as the first injectable PrEP for HIV prevention, offering an alternative to dail...

 mercks-new-hiv-treatment-works-as-well-as-top-drug-in-late-trials

Merck's two-drug HIV regimen doravirine/islatravir maintained viral suppression and matched Gilead's Biktarvy in Phase ...

 gilead-presents-latest-clinical-data-on-lenacapavir-biktarvy-and-novel-long-acting-hiv-combinations-at-eacs-2025

 New Data Showcase Safety Profile of Twice-Yearly Lenacapavir for Pre-Exposure Prophylaxis (PrEP) with Other Medications and Re...

 gilead-sciencesarcus-biosciences-investigational-cancer-drug-shows-overall-survival-of-around-27-months

Arcus Biosciences reports 26.7-month median survival and 59% response rate in Phase 2 cancer study with domvanalimab combinatio...

 gilead-coinbase-rocket-lab-and-a-tech-stock-on-cnbcs-final-trades

On CNBC's "Halftime Report Final Trades," Rob Sechan, CEO of NewEdge Wealth, named Gilead Sciences as his final trade.

 citigroup-maintains-buy-on-gilead-sciences-raises-price-target-to-135

Citigroup analyst Geoff Meacham maintains Gilead Sciences (NASDAQ:GILD) with a Buy and raises the price target from $125 to ...

 gilead-says-for-q3-co-currently-expects-1704m-in-acquired-iprd-expenses-co-sees-acquired-iprd-expenses-to-represent-charge-of-about-011-to-both-gaap-and-non-gaap-eps

- SEC Filing

 gilead-reaches-settlement-to-block-biktarvy-generics-until-2036

Gilead Sciences settled patent disputes with Lupin, Cipla, and Laurus, delaying U.S. generic entry of HIV drug Biktarvy until A...

 gilead-settles-patent-disputes-to-block-generic-biktarvy-launch-in-us-until-april-2036

On October 6, 2025, Gilead Sciences, Inc., a Delaware corporation ("Gilead"), announced that it has entered into settle...

 gilead-sciences-entered-into-settlement-agreement-to-resolve-patent-litigation-with-lupin-cipla-and-laurus-labs-for-biktarvy

https://www.sec.gov/ix?doc=/Archives/edgar/data/882095/000088209525000041/gild-20251006.htm

 these-3-pharma-stocks-are-rallying--and-still-trade-absurdly-cheap

Health care stocks are rallying, but Pfizer, Merck and Bristol-Myers still trade below 10x forward P/E — a rare market discount.

 gilead-pledges-65m-to-boost-stem-education-and-close-americas-skills-gap

Gilead Sciences, Inc. (NASDAQ: GILD) today announced that it has committed more than $6.5 million in grant funding toward stren...

 jp-morgan-maintains-overweight-on-gilead-sciences-raises-price-target-to-145

JP Morgan analyst Chris Schott maintains Gilead Sciences (NASDAQ:GILD) with a Overweight and raises the price target from $1...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION